RECURSION PHARMACEUTICALS-A (RXRX) Stock Income Statement
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 58.84M | 44.58M | 39.84M | 10.18M | 3.96M | |||
| Cost Of Goods | 45.24M | 42.59M | 48.28M | N/A | N/A | |||
| Gross Profit | 13.60M | 1.99M | -8.43M | N/A | N/A | |||
| Operating Expenses | 492.61M | 350.85M | 237.29M | 192.95M | 88.58M | |||
| Research and Development | 295.62M | 208.37M | 141.27M | 125.98M | 61.54M | |||
| Selling, General, and Administrative Expenses | 178.18M | 133.98M | 95.65M | 66.67M | 27.04M | |||
| Operating Income | -479.00M | -348.86M | -245.73M | -182.77M | -84.62M | |||
| Interest Income/Expense | 14.19M | 19.02M | 6.20M | -2.88M | -1.02M | |||
| Other Income/Expense | 30.00K | -1.09M | 50.00K | 0.00 | -480.00K | |||
| Non Recurring Items | N/A | -1.20M | 0.00 | -830.00K | -880.00K | |||
| Income Before Taxes | -464.79M | -332.13M | -239.48M | -186.48M | -87.01M | |||
| Income Tax | -1.13M | -4.06M | N/A | N/A | N/A | |||
| Net Income | -463.66M | -328.07M | -239.48M | -186.48M | -87.01M | |||
| EBITDA | -442.51M | -324.46M | -233.97M | -174.36M | -80.18M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.69 | -1.58 | -1.36 | -1.49 | -0.54 | |||
| Non GAAP EPS | -1.66 | -1.57 | -1.37 | N/A | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 23.12% | 4.46% | -21.16% | N/A | N/A | |||
| Profit Margin | -788.02% | -735.99% | -601.10% | -1831.83% | -2197.22% | |||
| Operating Profit Margin | -814.09% | -782.64% | -616.79% | -1795.38% | -2136.87% | |||
All data in USD